{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:26:27Z","timestamp":1784579187213,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,6,12]],"date-time":"2008-06-12T00:00:00Z","timestamp":1213228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,6,12]],"date-time":"2008-06-12T00:00:00Z","timestamp":1213228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1038\/leu.2008.145","type":"journal-article","created":{"date-parts":[[2008,6,12]],"date-time":"2008-06-12T10:11:14Z","timestamp":1213265474000},"page":"1680-1684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["A pilot pharmacokinetic study of oral azacitidine"],"prefix":"10.1038","volume":"22","author":[{"given":"G","family":"Garcia-Manero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M L","family":"Stoltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,6,12]]},"reference":[{"key":"BFleu2008145_CR1","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB . Gene silencing in cancer in association with promoter hypermethylation. N Eng J Med 2003; 349: 2042\u20132054.","journal-title":"N Eng J Med"},{"key":"BFleu2008145_CR2","first-page":"202","volume":"84","author":"PA Jones","year":"1983","unstructured":"Jones PA, Taylor SM, Wilson VL . Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 1983; 84: 202\u2013211.","journal-title":"Recent Results Cancer Res"},{"key":"BFleu2008145_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0092-8674(83)90327-6","volume":"33","author":"DV Santi","year":"1983","unstructured":"Santi DV, Garrett CE, Barr PJ . On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 1983; 33: 9\u201310.","journal-title":"Cell"},{"key":"BFleu2008145_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1042\/bj3070087","volume":"307","author":"S Gabbara","year":"1995","unstructured":"Gabbara S, Bhagwat AS . The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem J 1995; 307: 87\u201392.","journal-title":"Biochem J"},{"key":"BFleu2008145_CR5","first-page":"87","volume":"28","author":"AP Bird","year":"1996","unstructured":"Bird AP . The relationship of DNA methylation to cancer. Cancer Surv 1996; 28: 87\u2013101.","journal-title":"Cancer Surv"},{"key":"BFleu2008145_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/5947","volume":"21","author":"PA Jones","year":"1999","unstructured":"Jones PA, Laird PW . Cancer epigenetics comes of age. Nat Genet 1999; 21: 163\u2013167.","journal-title":"Nat Genet"},{"key":"BFleu2008145_CR7","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1038\/sj.onc.1205602","volume":"21","author":"AR Karpf","year":"2002","unstructured":"Karpf AR, Jones DA . Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002; 21: 5496\u20135503.","journal-title":"Oncogene"},{"key":"BFleu2008145_CR8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood.V90.4.1403","volume":"90","author":"T Uchida","year":"1997","unstructured":"Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997; 90: 1403\u20131409.","journal-title":"Blood"},{"key":"BFleu2008145_CR9","first-page":"722","volume":"56","author":"JG Herman","year":"1996","unstructured":"Herman JG, Jen J, Merlo A, Baylin SB . Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996; 56: 722\u2013727.","journal-title":"Cancer Res"},{"key":"BFleu2008145_CR10","first-page":"2760","volume":"30","author":"LH Li","year":"1970","unstructured":"Li LH, Olin EJ, Buskirk HH, Reineke LM . Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970; 30: 2760\u20132769.","journal-title":"Cancer Res"},{"key":"BFleu2008145_CR11","first-page":"2770","volume":"30","author":"LH Li","year":"1970","unstructured":"Li LH, Olin EJ, Fraser TJ, Bhuyan BK . Phase specificity of 5-azacytidine against mammalian cells in tissue culture. Cancer Res 1970; 30: 2770\u20132775.","journal-title":"Cancer Res"},{"key":"BFleu2008145_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1634\/theoncologist.6-suppl_5-8","volume":"6","author":"LR Silverman","year":"2001","unstructured":"Silverman LR . Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 2001; 6: 8\u201314.","journal-title":"Oncologist"},{"key":"BFleu2008145_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/jez.1402280212","volume":"228","author":"PA Jones","year":"1983","unstructured":"Jones PA, Taylor SM, Wilson V . DNA modification, differentiation, and transformation. J Exp Zool 1983; 228: 287\u2013295.","journal-title":"J Exp Zool"},{"key":"BFleu2008145_CR14","first-page":"1324","volume":"87","author":"G Leone","year":"2002","unstructured":"Leone G, Teofili L, Voso MT, L\u00fcbbert M . DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002; 87: 1324\u20131341.","journal-title":"Haematologica"},{"key":"BFleu2008145_CR15","first-page":"A12","volume":"68","author":"LR Silverman","year":"1994","unstructured":"Silverman LR, Holland JF, Demakos EP, Peterson B, Nelson DA, Clamon G et al. Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol 1994; 68: A12, (abstract 46).","journal-title":"Ann Hematol"},{"key":"BFleu2008145_CR16","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/0006-2952(73)90137-8","volume":"22","author":"BA Chabner","year":"1973","unstructured":"Chabner BA, Drake JC, Johns DG . Deamination of 5-azacitidine by a human leukemia cell cytidine deaminase. Biochem Pharmacol 1973; 22: 2763\u20132765.","journal-title":"Biochem Pharmacol"},{"key":"BFleu2008145_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/carcin\/21.3.461","volume":"21","author":"KD Robertson","year":"2000","unstructured":"Robertson KD, Jones PA . DNA methylation: past, present and future directions. Carcinogenesis 2000; 21: 461\u2013467.","journal-title":"Carcinogenesis"},{"key":"BFleu2008145_CR18","unstructured":"Pharmion Corporation. Azacitidine Investigator's Brochure, 5th edn. Boulder, CO, 2007."},{"key":"BFleu2008145_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0091270004271947","volume":"45","author":"G Marcucci","year":"2005","unstructured":"Marcucci G, Silverman L, Eller M, Lintz L, Beach CL . Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005; 45: 597\u2013602.","journal-title":"J Clin Pharmacol"},{"key":"BFleu2008145_CR20","doi-asserted-by":"publisher","first-page":"790a","DOI":"10.1182\/blood-2005-03-1076","volume":"106","author":"L Silverman","year":"2005","unstructured":"Silverman L, McKenzie D, Peterson B, Demakos E, Malone N, Holland J et al. Azacitidine prolongs survival and time to AML transformation in high-risk myeloblastic syndrome (MDS) patients \u2a7e65 years of age. Blood 2005; 106: 790a, (abstract 2524).","journal-title":"Blood"},{"key":"BFleu2008145_CR21","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LA Silverman","year":"2002","unstructured":"Silverman LA, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429\u20132440.","journal-title":"J Clin Oncol"},{"key":"BFleu2008145_CR22","doi-asserted-by":"crossref","unstructured":"Fenaux P, Mufti GJ, Finelli C, Giagounidis A, Schroch R, List AF et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional car regimens (CCR): results of the AZA-001 phase III study. American Society of Hematology Annual Meeting Proceedings. Blood 2007; 110: 250a (abstract: 817).","DOI":"10.1182\/blood.V110.11.817.817"},{"key":"BFleu2008145_CR23","doi-asserted-by":"crossref","unstructured":"Soriano A, Braiteh F, Garcia-Manero G, Camacho L, Hong D, Moulder S et al. Combination of 5-azacytidine (5-AZA) and valproic acid (VPA) in advanced solid cancers: A phase I study. J Clin Oncol 2007; 25: 149s (abstract: 3547).","DOI":"10.1200\/jco.2007.25.18_suppl.3547"},{"key":"BFleu2008145_CR24","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F et al. Safety and clinical activity of the combination of 5-azcytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110: 2302\u20132308.","journal-title":"Blood"},{"key":"BFleu2008145_CR25","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1182\/blood-2006-03-009548","volume":"108","author":"S Gore","year":"2006","unstructured":"Gore S, Jiemjit A, Silverman L, Aucott T, Baylin S, Carraway H et al. Combined methyltransferase\/histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMoL, and AML: clinical response, histone acetylation and DNA damage. American Society of Hematology Annual Meeting Proceedings. Blood 2006; 108: 1569, (abstract 517).","journal-title":"Blood"},{"key":"BFleu2008145_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1365-2141.1989.tb07734.x","volume":"72","author":"C Dunbar","year":"1989","unstructured":"Dunbar C, Travis W, Kan YW, Nienhuis A . 5-Azacytidine treatment in a beta (0)-thalassaemic patient unable to be transfused due to multiple alloantibodies. Br J Haematol 1989; 72: 467\u2013468.","journal-title":"Br J Haematol"},{"key":"BFleu2008145_CR27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/blood.V66.3.527.527","volume":"66","author":"GJ Dover","year":"1985","unstructured":"Dover GJ, Charache S, Boyer SH, Vogelsang G, Moyer M . 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood 1985; 66: 527\u2013532.","journal-title":"Blood"},{"key":"BFleu2008145_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1749-6632.1985.tb17191.x","volume":"445","author":"GJ Dover","year":"1985","unstructured":"Dover GJ, Charache S, Nora R, Boyer SH . Progress toward increasing fetal hemoglobin production in man: experience with 5-azacytidine and hydroxyurea. Ann N Y Acad Sci 1985; 445: 218\u2013224.","journal-title":"Ann N Y Acad Sci"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2008145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2008145","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2008145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:08:39Z","timestamp":1648724919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2008145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,12]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["BFleu2008145"],"URL":"https:\/\/doi.org\/10.1038\/leu.2008.145","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,12]]},"assertion":[{"value":"9 May 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}